Immunogenicity Study of the Antibody Persistence and Booster Effect of PENTAXIM(TM) at 18 Months of Age Following a Primary Series of DTaP-IPV-HB-PRP~T Combined Vaccine or of PENTAXIM(TM) and ENGERIX B(R) PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants. [EXTENSION of 700041122]

Trial Profile

Immunogenicity Study of the Antibody Persistence and Booster Effect of PENTAXIM(TM) at 18 Months of Age Following a Primary Series of DTaP-IPV-HB-PRP~T Combined Vaccine or of PENTAXIM(TM) and ENGERIX B(R) PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants. [EXTENSION of 700041122]

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2013

At a glance

  • Drugs Hib-DTaP-poliovirus vaccine (Primary)
  • Indications Diphtheria; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 15 Dec 2009 Actual end date (Sep 2007) and actual number of patients (459) added as reported by ClinicalTrials.gov.
    • 15 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top